GT Biopharma appoints Alan L. Urban to Board and Audit Committee

GT Biopharma, Inc.

Alan L. Urban appointed to fill vacant Board seat and serve on Audit Committee effective June 9, 2022.
Board determined Urban qualifies as independent director under Nasdaq rules.
Urban has 25+ years finance/accounting experience, including CFO at Research Solutions (RSSS) and ReachLocal (RLOC).
Urban is a CPA (inactive) since 1998; holds B.S. in Accounting from California State University, Northridge.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alan L. Urban

Director

GTBP · GT Biopharma, Inc.

Effective: 2022-06-09
Filed: June 10, 2022, 7:59 PM ET

Effective June 9, 2022, pursuant to the authority granted under the Registrant’s Amended and Restated Bylaws, the Registrant’s Board of Directors (“Board”) appointed Alan L. Urban to fill a vacant seat on the Board and to serve as a member of the Audit Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan L. Urban was appointed as Director at GT Biopharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective June 9, 2022, pursuant to the authority granted under the Registrant’s Amended and Restated Bylaws, the Registrant’s Board of Directors (“Board”) appointed Alan L. Urban to fill a vacant seat on the Board and to serve as a member of the Audit Committee of the Board.

View on SEC.gov

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-016394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.